Patents by Inventor Rina Hashimoto

Rina Hashimoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • siRNA based on RNA sequence of SARS-CoV-2 and use thereof
    Publication number: 20250129368
    Abstract: The present disclosure provides siRNA that suppresses proliferation of new coronaviruses (SARS-COV-2). The siRNA disclosed herein includes: a sense strand; and an antisense strand. The sense strand includes a target sequence comprising 19 to 23 bases in which a base at a 5? terminal is guanine (G) or cytosine (C), and an overhang comprising 2 to 4 bases added to a 3? terminal side of the target sequence. The antisense strand includes a sequence complementary to the target sequence, and an overhang comprising 2 to 4 bases added to a 3? terminal side of the complementary sequence. Here, at least a part of the target sequence contains at least a part of a base sequence encoding a signal peptide region of a spike protein (S protein) of SARS-COV-2.
    Type: Application
    Filed: December 17, 2024
    Publication date: April 24, 2025
    Inventors: Tetsuhiko Yoshida, Nahoko Baileykobayashi, Kazuo Takayama, Rina Hashimoto, Yoshinori Yoshida
  • siRNA based on RNA sequence of SARS-CoV-2 and use thereof
    Patent number: 12209242
    Abstract: The present disclosure provides siRNA that suppresses proliferation of new coronaviruses (SARS-CoV-2). The siRNA disclosed herein includes: a sense strand; and an antisense strand. The sense strand includes a target sequence comprising 19 to 23 bases in which a base at a 5? terminal is guanine (G) or cytosine (C), and an overhang comprising 2 to 4 bases added to a 3? terminal side of the target sequence. The antisense strand includes a sequence complementary to the target sequence, and an overhang comprising 2 to 4 bases added to a 3? terminal side of the complementary sequence. Here, at least a part of the target sequence contains at least a part of a base sequence encoding a signal peptide region of a spike protein (S protein) of SARS-CoV-2.
    Type: Grant
    Filed: July 12, 2022
    Date of Patent: January 28, 2025
    Assignees: TOAGOSEI CO., LTD., KYOTO UNIVERSITY
    Inventors: Tetsuhiko Yoshida, Nahoko Baileykobayashi, Kazuo Takayama, Rina Hashimoto, Yoshinori Yoshida
  • siRNA based on RNA sequence of SARS-CoV-2 and use thereof
    Publication number: 20230047473
    Abstract: The present disclosure provides siRNA that suppresses proliferation of new coronaviruses (SARS-CoV-2). The siRNA disclosed herein includes: a sense strand; and an antisense strand. The sense strand includes a target sequence comprising 19 to 23 bases in which a base at a 5? terminal is guanine (G) or cytosine (C), and an overhang comprising 2 to 4 bases added to a 3? terminal side of the target sequence. The antisense strand includes a sequence complementary to the target sequence, and an overhang comprising 2 to 4 bases added to a 3? terminal side of the complementary sequence. Here, at least a part of the target sequence contains at least a part of a base sequence encoding a signal peptide region of a spike protein (S protein) of SARS-CoV-2.
    Type: Application
    Filed: July 12, 2022
    Publication date: February 16, 2023
    Inventors: Tetsuhiko Yoshida, Nahoko Baileykobayashi, Kazuo Takayama, Rina Hashimoto, Yoshinori Yoshida